Recently, molecular weights of many drugs and their candidates have been increasing by the progress of combinatorial chemistry and high throughput screening (HTS). Therefore, it is known that water solubility of these drug candidates tended to decrease because of their large molecular size and high lipophilicity. As drug solubility is one of the most important factors affecting the intestinal drug absorption after oral administration, the poor solubility of these drug candidates is one of the most serious problems to achieve the high bioavailability of these drug candidates.
Many strategies have been examined to overcome the low water solubility of drugs and their candidates. These strategies include solid dispersion, salt formulation, emulsion and liposomes and pharmaceutical excipients (solubilizing agents). 1) Of these strategies, solubilizing agents have been utilized to improve the solubility of poorly water-soluble drugs and their bioavailability (BA) after oral administration. These solubilizing agents were considered inert substances that would be mainly used as diluents, fillers, binders, lubricants, coatings, solvents, dyes, and in the manufacture of drug products. However, the solubilizing agents may sometimes alter the intestinal membrane integrity and affect the function of transporters including P-glycoprotein (P-gp) and peptide transporter (PEPT1) in the intestine. Indeed, our previous study demonstrated that sodium taurocholate (NaTC), a natural surfactant and a bile salt, could increase the intestinal absorption of phenol red, a poorly absorbable compound in rats and cause the intestinal membrane damage as evaluated by the release amount of protein and phospholipid from the intestinal membranes. 2, 3) In addition, the intestinal absorption of insulin, gentamicin and other hydrophilic drugs was improved in the presence of Labrasol, one of the typical solubilizing agent. [4] [5] [6] Furthermore, more recently, we found that NaTC and Labrasol at higher concentrations might alter the intestinal barrier functions and increase the intestinal absorption of 5(6)-carboxyfluorescein (CF) and fluorescein isothiocyanate-labeled dextran with an average molecular weight of 4000 (FD4) in rats. 7) As for the effect of solubilizing agents on the function of transporters, it has been reported that several common excipients could modulate the activity of P-gp, a typical efflux transporter. 8) Furthermore, our previous study indicated that Cremophor EL, Tween 80, n-dodecyl-b-D-maltopyranoside (LM), polyethyleneglycol (PEGs) and Labrasol also inhibited the function of P-gp in the intestine, thereby reducing the secretory transport of rhodamine123 and other P-gp substrates. [9] [10] [11] [12] Therefore, it is important to find out a suitable solubilizing agent, which has high potency and no influence on the function of integrity and transporters in the intestine.
Based on the background, Wellsolve, a novel solubilizing agent, has recently been developed by Celeste Co., Ltd., although the components of this agent were not disclosed. In the preliminary studies, Wellsolve could improve the solubility of some poorly water-soluble drugs and increased the intestinal absorption of these drugs. However, the effects of Wellsolve on the intestinal membrane integrity and the functions of transporters have not been examined and reported until now. In addition, the safety of this new solubilizing agent to the intestinal membranes has not been studied. Therefore, in this study, we examined the effect of Wellsolve with various concentrations on the transport and absorption of CF, rhodamine123, (a P-gp substrate), cephalexin (a substrate of PEPT1). In addition, in order to confirm the safety of Wellsolve, we also examined the intestinal membrane damage by measuring the release of protein and lactate dehydrogenase (LDH) from the intestinal membranes. Finally, the effect of Wellsolve on the intestinal absorption of griseofulvin, a poorly water-soluble drug (a BCS class II drug), was examined by the in situ closed loop method to confirm its effectiveness for improving the intestinal absorption of poorly water-soluble drugs. Preparation of Drug Solution CF and Rhodamine123 were dissolved in N-(2-hydroxyethyl)piperazine-NЈ-2-ethanesulfonic acid (Hepes)-Tris buffer solution at pH 7.4 to yield a final concentration of 10 mM, respectively, while cephalexin was dissolved in Hepes-Tris buffer to a final concentration of 1 mM. In the case of cephalexin, the pH of donor side of the in vitro diffusion chamber was maintained at pH 6.0, while the pH in the receiver side was 7.4 to provide the H ϩ gradient from the donor side to the receiver side. 13, 14) Griseofulvin was dissolved in 20% (v/v) dimethyl sulfoxide (DMSO) to yield a final concentration of 0.5 mg/ml. The concentrations of these drugs were selected based on their limit of detection by in vitro and in situ absorption studies. A suspension of griseofulvin formulation was also prepared in undissolved form in Hepes-Tris buffer (pH 7.4) as a control group. The saturated solubility of griseofulvin without any solubilizing agent was 0.1 mg/ml. Wellsolve with series of concentrations range from 0.01 to 20% (v/v) was added to rhodamine123 solution, while the concentrations of 1%, 5%, 10% and 20% (v/v) of Wellsolve were added to CF and cephalexin solution. Furthermore, we added 10% (v/v) Wellsolve to examine its effectiveness on the intestinal absorption of griseofulvin, a poorly water-soluble drug in rats. However, the solubility of griseofulvin in 20% (v/v) DMSO solution (0.5 mg/ml) was not increased even in the presence of 10% (v/v) Wellsolve.
MATERIALS AND METHODS

Materials
Transport of Model Drugs across the Intestinal Membranes by an in Vitro Diffusion Chamber System The in vitro transport of CF, rhodamine123 and cephalexin across the rat intestinal membrane with or without Wellsolve was evaluated by a modified diffusion chamber method (Corning Coster Corp.) 15) Male Wistar rats, weighing 250-280 g, were fasted overnight and anesthesized with sodium pentobarbital (32 mg/kg body weight, intraperitoneally (i.p.)). The studies have been carried out in accordance with the guidelines of the animal ethics committee at Kyoto Pharmaceutical University. The intestine was exposed through a midline abdominal incision, removed and washed with phosphate buffered saline (PBS). Intestinal segments were isolated and the segments were cut open. Then, the muscle layer was stripped, the intestinal sheets were mounted to the pins of the cell, and the half-cells were clamped together. Drug solution (7 ml) was added to the donor side, whereas the same volume of drug free buffer was added to the receiver side. Each side of the chamber was aerated with 95% O 2 and 5% CO 2 gas in order to mix each solution and to maintain the viability of the membrane. The temperature was maintained at 37°C throughout the experiment. At predetermined times intervals up until 120 min, 0.1 ml aliquots were taken from the receiver side, and this was immediately replaced with an equal volume of buffer solution and then drugs were assayed. Apparent permeability coefficient (P app ) was calculated as the following equation.
Where P app is apparent permeability coefficient (cm/s), the permeability flux is the slope of linear portion of cumulative transport amount to time at the steady state (pmol/min), Area is the area of diffusion chamber for transport, 1.78 cm 2 , C 0 is the drug concentration before transport (pmol/ml).
The transepithelial electrical resistance (TEER) values of rat intestinal membranes were measured by an in vitro diffusion chamber and an electrophysiological method using stripped rat intestinal membranes. At different time intervals up to 1 h and 30 min, the transmucosal potential differences (PD) and short circuit current (Isc) were measured by a short-circuit current amplifier (CEZ-9100, NIHON KOH-DEN, Tokyo, Japan) respectively, and the tissue electrical resistance (Rm) was then calculated following Ohm's law. The initial value of TEER value in the rat intestinal membrane was 46.4Ϯ7.9 ohm · cm 2 and this value was almost maintained in the control studies (without any drug and any adjuvant) during the transport studies up to 90 min, confirming that the viability of the intestinal membrane was maintained during the transport studies.
Intestinal Absorption of CF and Griseofulvin by an in Situ Closed Loop Method Intestinal absorption of CF and griseofulvin was examined by an in situ closed loop method, as reported previously. 15, 16) Male Wistar rats (250-280 g) were fasted for about 16 h before the experiment and anesthetized with sodium pentobarbital (32 mg/kg body weight, i.p.) throughout the experiment. The intestine was exposed through the midline abdominal incision. After ligating the bile duct, a segment of ileum (about 20 cm long) was isolated and washed with Hepes-Tris buffer solution, then tied off at both ends to form a closed loop. The rats were placed under a heating lamp to maintain the body temperature around 37°C. CF solution (0.125 mg/rat) with or without Wellsolve (1-20%, (v/v)) or griseofulvin solution (1.5625 mg/rat) in the absence or presence of 10% (v/v) Wellsolve were introduced into the intestinal loop through a cannulated opening in the proximal part of the loop, which was then closed by closing the tubing with forceps. The jugular vein was exposed and blood samples (ca. 0.2 ml) were collected into heparinized syringes at predetermined time intervals up until 240 min. Samples were immediately centrifuged at 10000 rpm for 5 min to obtain the plasma fraction (100 ml), which was then kept in ice until determination. The peak concentration (C max ) and the time to reach the peak concentration (T max ) were determined directly from the plasma concentration-time curves. The area under the curve (AUC ) was calculated by the trapezoidal method from zero to the final sampling time (240 min). The extent of bioavailability was calculated as follows:
Where F is bioavailability (%) and D is the dose administered.
Determination (Assay) of Drugs The fluorescence intensities of CF and rhodamine123 were measured with a fluorescence spectrophotometer (Spectrafluor Plus, TECAN, Switzerland) at an excitation wavelength of 485 nm and an emission wavelength of 535 nm, respectively. The concentrations of cephalexin and griseofulvin were determined with an HPLC system equipped with an analytical column from Nacalai Tesque (Cosmosil, 4.6 mmϫ150 mm, 5 m m particle), a Shimadzu LC-10 pump system, a Shimadzu LC-10 autoinjector, a Shimadzu RF-10A or LC-10 detector and a Shimadzu CR-6A integrator.
Biological substances were removed from samples of in vitro studies before being injected onto HPLC in order to prevent these substances from entering the HPLC column. One thousand microliters of acetonitril (ACN) was added to 100 ml samples in 1 ml tube. Then, the samples were vortexed and centrifuged at 13000 rpm for 5 min. The supernatants were transferred into a clean test tube and evaporated in a centrifugal evaporator at 60°C. The residue was then dissolved with 100 ml of a mobile phase solution (methanol : acetate bufferϭ2 : 8). Finally, 20 ml of samples were injected onto the HPLC system. The mobile phase of 1 mM cephalexin was acetic acid buffer (pH 6.0) : methanolϭ 80 : 20. The flow rate was 0.5 ml/min. The concentrations of cephalexin were determined by HPLC analysis with an UV detector (Shimadzu SPD-20A) at 262 nm wavelength. For the determination of griseofulvin, the mobile phase was 0.1 M acetic acid : acetonitrile (55 : 45, v/v) and the flow rate was 0.5 ml/min. The concentration of griseofulvin was determined using an UV detector (Shimadzu SPD-20A) at 293 nm.
Assessment of Membrane Damage
As an indicator of cell damage, the liberation of the cytosolic enzyme LDH and protein was determined, as reported previously. 18, 19) At the end of 4 h of in situ closed loop method experiment, the perfusate in the intestine was withdrawn for the determination of the release of protein and LDH. The LDH activity was determined using an assay kit LDH CII (Wako Pure Chemical Industries, Osaka, Japan) while the protein concentration was determined by BCA TM Protein Assay Kit (Pierce Tech., WI, U.S.A.) using bovine serum albumin as a standard.
Statistical Analysis Results were expressed as the meanϮS.E. and statistical significance was performed with analysis of variance (ANOVA) for multiple comparisons with the minimum level of significance with pϽ0.05.
RESULTS
Effect of Wellsolve on the Transport of CF across the Intestinal Membranes by an in Vitro Diffusion Chamber
System and an in Situ Closed Loop Method Firstly, we examined the effect of Wellsolve on the intestinal transport of CF by the in vitro modified diffusion chamber system. Figure 1 shows the time course of the transport of CF across the jejunum in the presence or absence of Wellsolve with concentrations of 1%, 5%, 10% and 20% (v/v). As shown in Fig. 1 , the time course of 1% and 5% (v/v) Wellsolve seemed to decrease significantly as compared with the control. On the other hand, 10% and 20% (v/v) Wellsolve showed almost no significant effect on the transport of CF across the intestinal membranes. Table 1 summarizes the effect of Wellsolve on the apparent permeability coefficient (P app ) of CF (10 mM) across the rat jejunum. The P app values of CF in the presence of 1% and 5% (v/v) Wellsolve significantly decreased nearly two folds, as compared with the control. However, 10% and 20% (v/v) of Wellsolve did not change the P app values of CF in the jejunal membranes. Figure 2 shows the plasma-concentration-time profiles of CF (0.5 mg/kg) with or without various concentrations of
1900 Vol. 32, No. 11 Table 2 , 20% (v/v) Wellsolve increased the AUC value and bioavailability (F %) of CF by 2.5 folds, as compared with the control. We observed that F % of CF with 1 to 10% (v/v) Wellsolve were below 10%, but was significantly increased in the presence of 20% (v/v) Wellsolve (F %ϭ16.1%), as compared with the control.
Effect of Wellsolve on the Transport of Rhodamine123 across the Intestinal Membranes by an in Vitro Diffusion Chamber System The effect of Wellsolve on the absorptive and secretory transport of rhodamine123 (a P-gp substrate) across the rat ileal membranes was examined by the in vitro diffusion chamber method. The concentrations of Wellsolve used in this study were over the range of 0.01 to 20% (v/v). In the previous study, we found that the absorptive transport of rhodamine123 was enhanced and its secretory transport was inhibited in the presence of 0.3 mM verapamil and 20 mM cyclosporin A, typical P-gp inhibitors, suggesting that the effect of some adjuvants on the function of P-gp can be evaluated using the in vitro diffusion chamber system. 10) As shown in Table 3 , rhodamine123 was much more permeable in the secretory direction than in the absorptive direction, and the secretory transport (P app ) of rhodamine123 was greater than its absorptive transport (P app ) in the control, indicating that the net movement of rhodamine123 across the rat ileum was preferentially in the secretory direction. The serosal to mucosal (secretory) transport of rhodamine123 was significantly inhibited in the presence of 1.0-20% (v/v) Wellsolve, while the mucosal to serosal (absorptive) transport was also reduced in its presence. In this case, we evaluated the transport direction of rhodamine123 by calculating the efflux ratio of rhodamine123. As is evident from the Table 3 , the efflux ratio of rhodamine123 decreased over the concentration range of 0.01 to 1.0% (v/v) Wellsolve and subsequently increased in the presence of 5 to 20% (v/v) Wellsolve. Overall, we found no clear increased and decreased effect of Wellsolve for the absorptive and secretory transport of rhodamine123 in the presence of Wellsolve, although verapamil and cyclosporin A, typical P-gp inhibitors, could increase the absorptive transport of rhodamine123 and decreased its secretory transport, as reported previously. 10) These findings suggest that Wellsolve might not affect the function of P-gp in the intestine, although the low concentration of Wellsolve reduced the efflux ratio of rhodamine123 in the intestine.
Effect of Wellsolve on the Transport of Cephalexin across the Intestinal Membranes by an in Vitro Diffusion Chamber System We examined the effect of Wellsolve with various concentrations on the transport of cephalexin (a PEPT1 substrate) in the rat jejunum. We used jejunum region in this study, because the intestinal absorption of cephalexin was site dependent, which is much higher in the upper segment of small intestine than that in the lower segment. 20, 21) As shown in Fig. 3 , no significant difference in the intestinal transport of cephalexin was observed in the presence of Wellsolve as compared with the control, although there was a slight increase in the transport of cephalexin with the concentration of 1%, 5% and 10% (v/v) Wellsolve. As shown in Table 4 , we observed that the P app value of cephalexin seemed to increase up to 10% (v/v) of Wellsolve and decrease when 20% (v/v) Wellsolve was used. However, this 
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Results are expressed as the meanϮS.E. of at least 3 experiments. N.S., no significant difference, compared with the control. Effect of Wellsolve on the Intestinal Membrane Toxicity We next examined the effect of Wellsolve on intestinal membrane toxicity by evaluating the total amount of LDH and protein released from the intestinal membranes with or without Wellsolve. Figure 4(a) indicates the LDH level at 4 h after the administration of 1%, 5%, 10% and 20% (v/v) Wellsolve. As shown in Fig. 4(a) , only 20% (v/v) Wellsolve significantly increased the LDH level as compared with the control, while we found no significant increase in the LDH level in the presence of 1-10% (v/v) of Wellsolve. Similarly, we also evaluated the amount of total protein level at 4 h released from the intestinal membranes in the presence of 1-20% (v/v) Wellsolve. As shown in Fig. 4(b) , we observed that 20% (v/v) Wellsolve significantly increased the total protein level at 4 h after its intestinal administration. However, Wellsolve at lower concentrations (1-10% (v/v)) did not enhance the total protein level in the intestine, as compared to control.
Effect of Wellsolve on the Intestinal Absorption of Griseofulvin
We finally evaluated the effect of Wellsolve on the intestinal absorption of griseofulvin, a poorly watersoluble drug (a BCS class II drug). We prepared a suspension (an undissolved form) of griseofulvin in Hepes-Tris buffer solution as a control group. The saturated solubility of griseofulvin in Hepes-Tris solution was 0.1 mg/ml. The solution formulations of griseofulvin were also prepared by the addition of 20% (v/v) DMSO or 20% (v/v) DMSO and 10% (v/v) Wellsolve. The solubility of griseofulvin in these formulations was improved (0.5 mg/ml) as compared with the control. As shown in Fig. 5 , the absorption of griseofulvin in the control was low. However, intestinal absorption of griseofulvin was much improved by 10.5 times by the addition of 20% (v/v) DMSO in the solution formulation. Moreover, the intestinal absorption of griseofulvin was further improved by the addition of 10% (v/v) Wellsolveϩ20% (v/v) DMSO and this formulation used in these studies was the optimal for improving the intestinal absorption of griseofulvin in rats. Table 5 shows the pharmacokinetics parameters of griseofulvin after its intestinal administration in different formulations. The bioavailability of griseofulvin in the control is only 1.3%, but its bioavailability was much improved by the addition of 20% (v/v) DMSO, as compared with the control. Moreover, the bioavailability of griseofulvin was further improved by the addition of both 20% (v/v) DMSO and 10% (v/v) Wellsolve and it was the greatest (27.1%) of these formulations used in these studies. However, the solubility of griseofulvin was not further improved even in the presence of 10% (v/v) Wellsolve. 
DISCUSSION
In general, drug transport across intestinal epithelial cells is basically mediated by the following processes: passive diffusion (transcellular or paracellular transport), carrier-mediated influx or efflux transport. In this study, we examined the effect of Wellsolve on the intestinal transport and absorption of CF (a passive transport compound via a paracellular pathway), rhodamine123 (a typical P-gp substrate) and cephalexin (a typical PEPT1 substrate) in rats.
At first, we examined the effect of Wellsolve on the intestinal barrier function using CF as a model drug. CF is one of the typical water-soluble and low molecular weight compounds and it is known to be mainly transported by a paracellular pathway. Therefore, the transport of CF across the intestinal membranes is a good index to predict the tightness of the tight-junction in the paracellular route. 22) In addition, the jejunal region of the intestine was chosen for the in vitro diffusion chamber study, because the jejunum is a major site of absorption of most drugs due to the largest surface area. 23) We found that 10-20% (v/v) Wellsolve had no remarkable effect on the transport of CF as compared with the control. Therefore, these findings suggest that Wellsolve at these concentrations might not affect the intestinal barrier function and intestinal transport of CF across the intestinal membrane via a paracellular pathway by the in vitro transport studies. On the other hand, we found that the transport of CF was significantly reduced in the presence of 1-5% (v/v) Wellsolve. The reason for this finding was not clearly understood. One possible mechanism is that there may exist an interaction between CF and some components of Wellsolve in the intestinal lumen. Alternatively, it may be possible that some components of Wellsolve may modulate the tightness of tight junctions, since CF is known to be mainly transported via a paracellular pathway. However, since the components of Wellsolve were not disclosed at present, we cannot get a direct evidence to support the speculation and the possibilities of these findings.
Unlike the in vitro transport studies of CF, we found that 20% (v/v) Wellsolve significantly increased the intestinal absorption of CF by 2.5 times by the in situ closed loop method, suggesting that high concentrations of Wellsolve might alter the intestinal barrier function to some extent in the in situ experimental condition. Therefore, we found some discrepancies between the result of the in vitro transport studies and the result of in situ absorption studies. These findings were not well correlated with previous study of Sugiyama et al. (1997) who reported that there was a good correlation between the cumulative amount of phenol red absorbed (in vitro modified Ussing chamber method) and the area under the curve (AUC) obtained from the in situ closed loop model. 24) From these findings, we suggest that there appears to be some correlation between in vitro and in vivo studies in certain conditions and circumstances, however, it did not apply to all drugs or solubilizing agents used. It may depend on the condition of the drugs, solubilizing agents and the environment itself. Lennernas et al. (1997) suggested that the differences in quantitative permeability values in the in vitro and in vivo model systems are partly explained by the differences between the available intestinal surface area for absorption, methodological differences such as oxygenation, viability of the membrane, thickness of the diffusional pathways, blood flow and stirring conditions in these two systems. 25) On the other hand, in the case of Labrasol, recent studies demonstrated that the activity of lipase was much greater in in vivo conditions than that in in vitro studies and the absorption enhancing effects of the digested components resulting from Labrasol were much greater than Labrasol itself. 26) If this phenomenon can also be observed in the case of Wellsolve, such differences may be related to the different absorption enhancing effect of Wellsolve in this study. Probably, such factors may affect the different results of in vitro and in situ absorption studies, although further studies are necessary to clarify the discrepancies.
P-gp is a membrane-bound transporter that mediates active transport, efflux of a wide range of structurally unrelated drugs and other xenobiotics out of the cells. Intestinal P-gp is located on the apical membranes of the epithelial cells. Utilizing the energy that is generated by hydrolysis of ATP, P-gp drives the efflux of various substrates against a concentration gradient and thus reduces their intracellular concentration. It has been demonstrated that the intestinal P-gp, an ATP-dependent multidrug efflux pump, can be an active secretion system or an absorption barrier by transporting some drugs from the intestinal cells into lumen. 27) Therefore, intestinal absorption of drugs that are secreted by a P-gp mediated efflux system can be improved by inhibiting the function of Pgp in the intestinal membrane and the oral bioavailability of a wide range of drugs can be increased. 28) Recently, it was reported that various pharmaceutical excipients including solubilizing agents could reduce the function of P-gp in the intestine, thereby improving the intestinal absorption of P-gp substrates. Indeed, previous studies indicated that 0.1% Cremophor EL, Tween 80 and n-dodecyl-b-D-maltopyranoside (LM) reduced the serosal to mucosal (secretory)/mucosal to serosal (absorptive) ratio of rhodamine123. 9) In addition, Lin et al. (2007) reported that 0.075 to 0.1% (v/v) Labrasol increased the absorptive transport of rhodamine123 and decreased its secretory transport.
11) Furthermore, our previous studies indicated that 0.1% (w/v) of PEG 20000 could increase the absorptive transport of methylprednisolone and quinidine across the intestinal membranes. 12) In this study, therefore, we examined the effect of Wellsolve on the function of P-gp in the intestine. We used rhodamine123 as a typical model of P-gp substrate, because this compound was easily assayed and widely used for evaluating the function of P-gp in the field of cancer chemotherapy as well as biopharmaceutics. 29) The ileum was used in this study because this segment showed a greater P-gp-mediated rhodamine123 transport which was about 2.5 to 5.0 fold higher than other regions. 30) Although 1 to 20% (v/v) Wellsolve reduced the secretory transport of rhodamine123, the absorptive transport of rhodamine123 was not changed in the presence of 0.01 to 1.0% (v/v) Wellsolve and it significantly decreased in the presence of 5.0 to 20% (v/v) Wellsolve. The decrease in the absorptive and secretory transport of rhodamine123 in the presence of high concentrations might be due to the high viscosity of the drug solution with high concentrations of Wellsolve that restrict the diffusion and transport of rhodamine123 in this viscous solution. Another contributing factor that might be responsible for this finding is that high concentration of Well-solve caused micelle formation and entrapped the rhodamine123 in its micelle that may decrease its transport in the ileum, although the components of Wellsolve were not disclosed and were unknown. Taken altogether, these findings indicate that Wellsolve had almost no inhibitory effect on the function of P-gp.
Cephalexin, which is a b-lactam antibiotic, is a typical substrate for PEPT1, and is mainly absorbed via PEPT1. PEPT1 is the low-affinity, high-capacity transporter and is highly expressed in the small intestine 31) and most abundant in the absorptive epithelial cells of the villi in the small intestine. 32) PEPT1 activity is influenced by the H ϩ gradient as a driving force and the pH-dependent conformation change. Passive diffusion also contributed to the absorption of cephalexin. The absorption of cephalexin is much higher in the upper segment of the small intestine, but under fed condition, PEPT1 is higher in the lower segment.
21) The transport of cephalexin was also assessed by an in vitro diffusion chamber method. The mucosal and serosal sides of the in vitro diffusion chamber were maintained at pH 6.0 and pH 7.4, respectively, to induce proton gradient.
As we can observe from the data, the transport of cephalexin was not affected in the presence of Wellsolve, although there was a slight increase in the transport of cephalexin by the addition of 5% and 10% (v/v) Wellsolve. Previously, Koga et al. (2002) reported that the transport of cephalexin was not affected by the presence of Gelucire 44/14 using the in vitro chamber method. 33) Therefore, our present finding was well correlated with the previous report and suggested that Wellsolve might not affect the function of the carrier-mediated transporter PEPT1.
In the membrane toxicity studies, we found that 1 to 10% (v/v) Wellsolve did not cause any membrane damage to the intestinal mucosa. However, 20% (v/v) Wellsolve significantly increased the release of LDH and protein from the intestinal membrane. This finding is also well correlated with the present result showing the enhanced intestinal absorption of CF with 20% (v/v) of Wellsolve. Measurement of the leakage of components from the cytoplasm into the outside medium has been accepted as a valid method to estimate the membrane damage. The release of protein and LDH from the intestinal mucosa was used as an index to assess intestinal membrane damage. 3, 34) Based on these findings, we suggest that Wellsolve below the concentration of 10% (v/v) is safe to be used as a solubilizing agent.
Based on these findings, we examined the effect of 10% (v/v) Wellsolve on the absorption of griseofulvin which has low solubility and high permeability characteristics. The intestinal absorption of griseofulvin significantly increased by the addition of 20% (v/v) DMSO, as compared with the control group (undissolved formulation) (Fig. 5) . In this case, we could prepare the solution of griseofulvin by the addition of 20% (v/v) DMSO, because 20% (v/v) DMSO were very effective for improving the solubility of griseofulvin. One possible mechanism for the enhanced bioavailability of griseofulvin in the presence of 20% (v/v) DMSO may be due to the intestinal membrane damage by its exposure to the intestinal membranes. However, in the preliminary studies, the activities of LDH released from the intestinal membranes in the control, 20% DMSO and 20% DMSOϩ10% Wellsolve were 2748.7Ϯ205.8 (mU/l), 2395.5Ϯ141.8 (mU/l) and 2503.1Ϯ
198.6 (mU/l), respectively. In addition, the amounts of protein released from the intestinal membranes in the control, 20% DMSO and 20% DMSOϩ10% Wellsolve were 234.3Ϯ51.2 (mg/ml), 240.0Ϯ24.0 (mg/ml) and 273.3Ϯ6.8 (mg/ml), respectively. Therefore, there was no significant difference in the LDH and protein released from the intestinal membranes in these three groups. These findings suggested that 20% DMSO and 20% DMSOϩ10% Wellsolve did not cause serious damage to the intestinal membranes and might not alter the intestinal transport and absorption of drugs. Taken these findings together, we conclude that 20% (v/v) DMSO can increase the solubility of griseofulvin, thereby improving its absorption from the gastrointestinal tract.
Moreover, our present study demonstrated that 10% (v/v) Wellsolve further improved the intestinal absorption of griseofulvin and the highest bioavailability of griseofulvin (27.1%) was observed in the presence of 20% (v/v) DMSO and 10% (v/v) Wellsolve (Table 5 ). Our preliminary studies indicated that the solubility of griseofulvin in 20% (v/v) DMSO solution (0.5 mg/ml) was not further improved even in the presence of 10% (v/v) Wellsolve. In addition, as shown in Fig. 4 , we found that 10% (v/v) Wellsolve did not cause any membrane damage to the intestinal epithelium. Therefore, these findings suggested that 10% Wellsolve might increase the intestinal permeability of griseofulvin, thereby improving its intestinal absorption from the gastrointestinal tract.
In conclusion, although high concentrations of Wellsolve might alter the intestinal barrier function and might cause intestinal membrane damage to some extent, this novel solubilizing agent at lower concentrations might be potent and safe for improving the solubility and absorption of poorly watersoluble drugs including griseofulvin.
